On October 15, 2023 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Congress (Press release, Arvinas, OCT 15, 2023, View Source [SID1234635966]). Bavdegalutamide is an investigational orally bioavailable PROTAC androgen receptor (AR) degrader and is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC). This update will be presented during a poster session at the annual congress being held from October 20-24, 2023, in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster session details are as follows:
Date: Sunday, October 22, 2023
Time: 12:00 – 1:00 p.m. CEST / 6:00 – 7:00 a.m. EDT
Presentation Number: 1803P
Speaker: Daniel Petrylak, M.D.
Phase 1/2 study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations.
For more information, visit the official ESMO (Free ESMO Whitepaper) Congress website here.
Investor Call & Webcast Details
Arvinas will host a conference and webcast call on Sunday, October 22 at 3 p.m. CEST/9 a.m. ET to discuss the poster presentation. A live audio webcast of the presentation and supporting material will be available on the Events & Presentations section in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Arvinas website following the presentation.
About bavdegalutamide (ARV-110)
Bavdegalutamide (ARV-110) is an investigational orally bioavailable PROTAC protein degrader designed to selectively target and degrade the androgen receptor (AR). Bavdegalutamide is being developed as a potential treatment for men with mCRPC.
Bavdegalutamide has demonstrated activity in preclinical models of AR mutation or overexpression, both potential mechanisms of resistance to currently available AR-targeted therapies.